Addition Therapeutics announced $100M in funding to advance genomic medicine for chronic and rare diseases.
Addition Therapeutics is advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases in large and rare populations, leveraging its PRINT technology which combines RNA therapeutics and gene therapies
Addition Therapeutics is advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases in large and rare populations, leveraging its PRINT technology which combines RNA therapeutics and gene therapies.